Pet Pharm Biotech Co., Ltd. (TPEX:7762)
Taiwan · Delayed Price · Currency is TWD 46.00
-2.00 (-4.17%)
At close: Jul 29, 2026
Pet Pharm Biotech Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 268.65 | 181.79 | 168.49 | 16.76 |
Short-Term Investments | 250.21 | 206.14 | - | - |
Cash & Short-Term Investments | 518.86 | 387.93 | 168.49 | 16.76 |
Cash Growth | 33.75% | 130.25% | 905.52% | - |
Receivables | 59.35 | 33.78 | 31.24 | 20.91 |
Inventory | 14.64 | 13.68 | 10.8 | 5.81 |
Prepaid Expenses | 2.06 | 2.12 | 2.61 | 4.79 |
Other Current Assets | 5.64 | 4.43 | 141.28 | 50.04 |
Total Current Assets | 600.55 | 441.93 | 354.4 | 98.31 |
Property, Plant & Equipment | 395.06 | 290.2 | 92.45 | 84.57 |
Goodwill | 8.24 | - | - | - |
Other Intangible Assets | 85.09 | 9.08 | 4.05 | 5.08 |
Long-Term Deferred Tax Assets | 2.83 | 2.09 | - | - |
Other Long-Term Assets | 255.27 | 16.76 | 36.67 | 3.93 |
Total Assets | 1,347 | 760.06 | 487.58 | 191.89 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 3.1 | 7.92 | 4.81 | 2.91 |
Current Portion of Long-Term Debt | 0.42 | 100 | - | - |
Current Portion of Leases | 11.19 | 6.42 | 6.57 | 4.58 |
Current Income Taxes Payable | 0.02 | - | - | - |
Current Unearned Revenue | 4.81 | 4.31 | 3.94 | 3.09 |
Other Current Liabilities | 36.72 | 21.41 | 16.99 | 8.88 |
Total Current Liabilities | 56.25 | 140.05 | 32.31 | 19.46 |
Long-Term Debt | 17.34 | - | - | - |
Long-Term Leases | 77.22 | 37.46 | 41.63 | 37.94 |
Long-Term Deferred Tax Liabilities | 0 | - | - | - |
Other Long-Term Liabilities | 0.55 | - | - | - |
Total Liabilities | 151.36 | 177.52 | 73.94 | 57.4 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 572.33 | 405.29 | 371.9 | 251.9 |
Additional Paid-In Capital | 574.88 | 78.72 | 150.01 | - |
Retained Earnings | 26.86 | 14.51 | -108.27 | -117.42 |
Comprehensive Income & Other | - | 84.03 | - | - |
Total Common Equity | 1,174 | 582.54 | 413.64 | 134.48 |
Minority Interest | 21.63 | - | - | - |
Shareholders' Equity | 1,196 | 582.54 | 413.64 | 134.48 |
Total Liabilities & Equity | 1,347 | 760.06 | 487.58 | 191.89 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 106.16 | 143.88 | 48.2 | 42.52 |
Net Cash (Debt) | 412.7 | 244.05 | 120.29 | -25.77 |
Net Cash Growth | 69.11% | 102.89% | - | - |
Net Cash Per Share | 7.54 | 5.90 | 3.99 | -1.02 |
Filing Date Shares Outstanding | 58.09 | 41.69 | 38.25 | 25.18 |
Total Common Shares Outstanding | 58.09 | 41.69 | 38.25 | 25.18 |
Working Capital | 544.3 | 301.88 | 322.1 | 78.85 |
Book Value Per Share | 20.21 | 13.97 | 10.81 | 5.34 |
Tangible Book Value | 1,081 | 573.47 | 409.59 | 129.4 |
Tangible Book Value Per Share | 18.60 | 13.76 | 10.71 | 5.14 |
Land | 172.41 | 172.41 | - | - |
Machinery | 147.9 | 93.4 | 80.44 | 83.92 |
Construction In Progress | 11.16 | 14.59 | - | - |
Leasehold Improvements | 73.48 | 51.47 | 39.47 | 35.83 |